This study examined the impact of patient education, led by a clinical pharmacist, on the management of gastroesophageal reflux disease (GERD), focusing on the disease itself, treatment benefits, causes, lifestyle changes, and overall improvement in quality of life. The research is a prospective observational study. For mild GERD (GERD A) patients, GSRS scores were 7.552 ± 3.63 at baseline, 3.724 ± 3.39 at follow-up 1, and 1.414 ± 2.95 at follow-up 2. Moderate GERD (GERD B) patients had scores of 11.042 ± 3.52, 5.792 ± 2.54, and 1.917 ± 3.01, respectively, while severe GERD (GERD C) patients scored 10.154 ± 3.955, 6.462 ± 3.71, and 3.00 ± 4.51. HRQL scores for mild patients were 26.069 ± 12.77 at baseline, 16.139 ± 12.19 at follow-up 1, and 8.138 ± 13.82 at follow-up 2. Moderate patients had scores of 30.33 ± 8.61, 17.918 ± 7.51, and 7.583 ± 8.40, while severe patients had scores of 35.846 ± 12.07, 22.308 ± 8.17, and 8.923 ± 7.51. The significant reduction in GSRS scores indicates an improvement in the health-related quality of life (HRQL) for GERD patients. The findings suggest that patient education plays an important role in reducing symptoms and increasing the quality of life of individuals suffering from GERD.
